2nd Quarter - Report
BELL & LINDSAY, INC. (FORMERLY WHITE HOUSE CONSULTING INC.) for AMERITOX
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Client
Income
$40,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 19, 2017 | $40,000 | Replaced |
| 2nd Quarter - Amendment | Jul 19, 2017 | $40,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Informing about the need for effective prescription drug monitoring to address the growing epidemic of prescription drug abuse.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BENSON HAYCOCK New | LegisInternSenReid/CommInternSenDemocraticMediaCenter |
| MARK F LINDSAY | EOP Office of Administration Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.